Home / Companies / News / China's Sinopharm says data 'better than expected' from it's COVID vaccine trial

China's Sinopharm says data 'better than expected' from it's COVID vaccine trial

Sinopharm (REUTERS) — Sinopharm **(REUTERS)**

1 min read . Updated: 11 Nov 2020, 06:46 PM IST Reuters

Sinopharm's unit CNBG has moved two vaccine candidates into Phase 3 clinical trials outside China in multiple countries including the UAE, Bahrain and Egypt
It did not offer details on the better-than-expected data, or specify which vaccine candidate the data are generated from

China National Pharmaceutical Group (Sinopharm) said on Wednesday the data from large-scale, late-stage clinical trials for its unit's COVID-19 vaccine are "better than expected".

Sinopharm's unit China National Biotec Group (CNBG) has moved two vaccine candidates into Phase 3 clinical trials outside China in multiple countries including the United Arab Emirates, Bahrain and Egypt involving more 50,000 participants in total.